Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,938
  • Shares Outstanding, K 59,230
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,140 K
  • 36-Month Beta 2.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.42
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/31/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/18
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.68 +22.06%
on 11/06/18
1.96 -57.65%
on 11/01/18
-0.69 (-45.39%)
since 10/12/18
3-Month
0.68 +22.06%
on 11/06/18
1.96 -57.65%
on 11/01/18
-0.62 (-42.76%)
since 08/13/18
52-Week
0.68 +22.06%
on 11/06/18
2.63 -68.44%
on 11/14/17
-1.52 (-64.68%)
since 11/13/17

Most Recent Stories

More News
OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

OncoSec Medical Inc., (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that TAVO(TM) will be featured in two poster sessions during the 2018 San Antonio...

ONCS : 0.83 (-3.49%)
Today's Research Reports on Stocks to Watch: Vericel and OncoSec Medical

NEW YORK, NY / ACCESSWIRE / November 7, 2018 / Vericel Corporation, a commercial-stage biopharmaceutical company, that researches, develops, manufactures, markets, and sells patient-specific expanded cellular...

ONCS : 0.83 (-3.49%)
VCEL : 16.44 (+2.56%)
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that the first patient has been treated in KEYNOTE-890, a Phase 2 clinical...

ONCS : 0.83 (-3.49%)
OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that preliminary clinical and immunological data from its ongoing KEYNOTE-695...

ONCS : 0.83 (-3.49%)
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Kellie Malloy Foerter to the position of Chief Clinical...

ONCS : 0.83 (-3.49%)
OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the publication of a study in the peer-reviewed journal, Nature Gene Therapy...

ONCS : 0.83 (-3.49%)
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated KEYNOTE-890, a Phase 2 clinical trial for the treatment...

ONCS : 0.83 (-3.49%)
OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the closing of the first $8 million tranche of its $15 million investment...

ONCS : 0.83 (-3.49%)
OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a...

ONCS : 0.83 (-3.49%)
Data from OncoSec's OMS-100 Clinical Trial Accepted for Oral Presentation at the 2018 Melanoma Bridge Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dr. Alain Algazi, Associate Professor of Medicine at UCSF, will present...

ONCS : 0.83 (-3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 0.91
1st Resistance Point 0.87
Last Price 0.83
1st Support Level 0.81
2nd Support Level 0.79

See More

52-Week High 2.63
Fibonacci 61.8% 1.89
Fibonacci 50% 1.66
Fibonacci 38.2% 1.42
Last Price 0.83
52-Week Low 0.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar